URGN Research and Charts

URGN - UroGen Pharma Ltd (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2026-02-10)

Last 21.67	Change ⇓ -0.23 (-1.05%)	Volume 305,369
	Open 21.90	High 22.25	Low 21.45

8EMA (Daily) 21.06	40EMA (Daily) 21.32	50EMA (Daily) 21.38	STO (Daily) 75.540	MACD Hist (Daily) 0.303
8EMA (Weekly) 21.166	40EMA (Weekly) 18.87	50EMA (Weekly) 18.12	STO (Weekly) 23.041	MACD Hist (Weekly) -0.500


Company Profile
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company's lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.